MetaCap

Korro Bio Inc. (KRRO)

NASDAQ: KRROHealth CareBiotechnology: Pharmaceutical PreparationsUSD

12.18-0.01 (-0.08%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KRRO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$167.18M
EPS (TTM)
-$8.89
52-week range
5.20 – 17.35
Day range
12.01 – 12.95
Volume / Avg
123.52K / 186.03K
Beta
—

52-week range

$5.20$17.35

KRRO stock today

Korro Bio (KRRO) closed at $12.18 on Nov 20, down 0.08% (-$0.01), versus the S&P 500's 3.70% decline. At this level, KRRO sits in the middle of its 52-week range of $5.20 to $17.35: 29.8% below the high, set on Nov 3, 2026 and 134.1% above the low. KRRO is up 52.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 93.9%.

Korro Bio has posted a net loss over the last twelve months (EPS of -$8.89), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Korro Bio

Company profile

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Ram Aiyar MBA, Ph.D.
Headquarters
Cambridge, MA
Employees
58
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Korro Bio generated $6.4 million in revenue, up 181.5% from fiscal 2024, its 2nd consecutive year of revenue growth. Korro Bio reported a net loss of $117.3 million, compared with a loss of $83.6 million a year earlier. Operating margin was -1906.4%.

Korro Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$6.39M$2.27M$0$0$14.07M
Growth+181.46%——-100.00%-61.96%
Net income$-117.26M$-83.58M$-81.17M$-58.03M$-84.69M
EPS (diluted)$-12.48$-9.37$-53.08$-227.42$-2.47

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$21.50+76.52%

  • Strong buy 2
  • Buy 8
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $35.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.98 vs $-1.14
Surprise
+14.04%

KRRO news

All KRRO news

Korro Bio peers

Health Care sector
KRRO peer companies
CompanyPrice% ChgMarket capCompare
ABEOAbeona Therapeutics Inc.2.42-1.22%$165.31Mvs KRRO
TRDAEntrada Therapeutics Inc.4.35-6.25%$170.30Mvs KRRO
EMISEmmis Acquisition Corp. Class A10.36+0.15%$163.36Mvs KRRO
SIGASIGA Technologies Inc.2.40-9.43%$172.45Mvs KRRO
VOGXVogenx Inc11.87-7.30%$176.33Mvs KRRO
NATRNature's Sunshine Products Inc.10.18+0.10%$176.41Mvs KRRO
ORMPOramed Pharmaceuticals Inc.3.57-3.25%$155.24Mvs KRRO
ADCTADC Therapeutics SA1.28-1.54%$180.05Mvs KRRO

Indexes, lists and sector

Korro Bio stock FAQ

What is Korro Bio's stock price today?

KRRO last traded at $12.18 as of Nov 20, 4:00 PM EST, down 0.08% on the day. Prices are delayed at least 15 minutes.

Does Korro Bio pay a dividend?

No. Korro Bio does not currently pay a regular cash dividend.

Who is Korro Bio's CEO?

Dr. Ram Aiyar MBA, Ph.D. is the chief executive officer of Korro Bio Inc., which has about 58 employees.

Has KRRO ever split its stock?

Yes. The most recent KRRO stock split was a 1-for-50 split on Nov 6, 2023.

What is the KRRO 52-week high?

The 52-week high for KRRO is $17.35 and the 52-week low is $5.20. The stock is currently 29.8% below its high.

Compare KRRO